颜红兵,余小平,霍勇

• 1:中国医学科学院阜外医院深圳医院冠心病中心
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心
• 3:北京大学第一医院心内科

摘要(Abstract)：

TALOS-AMI研究、HOST-EXAM研究和TAILOR-PCI延长期研究实际上是病理生物学导向下个体化抗血小板治疗的具体体现。临床实践中应对患者进行全面的病理生物学评价,确定实施降级治疗策略的时机,并且酌情动态调整。单药抗血小板治疗本质上属于降级治疗策略范畴,其实施也应遵循降级治疗策略原则。目前的循证医学证据不支持常规检测基因类型来指导选择抗血小板治疗。

关键词(KeyWords)： 冠心病;双联抗血小板治疗;病理生物学

Abstract:

Keywords:

基金项目(Foundation): 深圳市医学重点学科（2020—2024年）：心血管内科（SZXK001）;; 深圳市“医疗卫生三名工程”：中国医学科学院阜外医院颜红兵教授急性冠状动脉综合征诊治团队（SZSM201911017）

作者(Author): 颜红兵,余小平,霍勇

参考文献(References)：

• [1]Park MW,Kim CJ,Kim MC,et al.A prospective,multicentre,randomised,open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilized patients with acute myocardial infarction after percutaneous coronary intervention:rationale and design of the TALOS-AMI trial.Euro Intervention,2021,16(14):1170-1176.
• [2]Koo BK,Kang J,Park KW,et al.Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM):an investigatorinitiated,prospective,randomized,open-label,multicenter trial.Lancet,2021,397(10293):2487-2496.
• [3]Pereira NL,Farkouh ME,So D,et al.Eff ect of genotypeg uidedoral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention:the TAILOR-PCI randomized clinical trial.JAMA,2020,324(8):761-771.
• [4]颜红兵，霍勇.病理生物学导向是抗血小板治疗的未来方向.中国介入心脏病学杂志，2018,26(10):541-542.
• [5]Rodriguez F,Harrington RA.Management of antithrombotic therapy after acute coronary syndromes.N Engl J Med,2021,384(5):452-460.
• [6]Mullen L,Meah MN,Elamin A,et al.Risk of major bleeding with potent antiplatelet agents after an acute coronary event:a comparison of ticagrelor and clopidogrel in 5116 consecutive patients in clinical practice.J Am Heart Assoc,2021,10(8):e019467.
• [7]You SC,Rho Y,Bikdeli B,et al.Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.JAMA,2020,324(16):1640-1650.
• [8]Cuisset T,Deharo P,Quilici J,et al.Benefit of switched dual antiplatelet therapy after acute coronary syndrome:the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study.Eur Heart J,2017,38(41):3070-3078.
• [9]Deharo P,Quilici J,Camoin-Jau L,et al.Benefit of switching dual antiplatelet therapy after acute coronary syndrome according to on-treatment platelet reactivity:the TOPIC-VASP prespecified analysis of the TOPIC randomized study.JACCCardiovasc Interv,2017,10(24):2560-2570.
• [10]Virmani R,Kolodgie FD,Burke AP,et al.Lessons from sudden coronary death:a comprehensive morphological classification scheme for atherosclerotic lesions.Arterioscler Thromb Vasc Biol,2000,20(5):1262-1275.
• [11]Crea F,Libby P.Acute coronary syndromes:the way forward from mechanisms to precision treatment.Circulation,2017,136(12):1155-1166.
• [12]颜红兵，霍勇.急性冠状动脉综合征：认清本质，指导实践.中国介入心脏病学杂志，2014,22(1):1-3.
• [13]Lee H,Koo BK,Park KW,et al.A randomized clinical trial comparing long-term clopidogrel versus aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation:Design and rationale of the HOST-EXAM trial.Am Heart J,2017,185:17-25.
• [14]Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS guidelines on myocardial revascularization.Eur Heart J,2019,40(2):87-165.
• [15]Smith Jr SC,Benjamin EJ,Bonow RO,et al.AHA/ACCFsecondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease:2011update:a guideline from the American Heart Association and American College of Cardiology Foundation.Circulation,2011,124:2458-2473.
• [16]Antithrombotic Trialists'Collaboration.Collaborative Metaanalysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324(7329):71-86.
• [17]Baigent C,Blackwell L,Collins R,et al.Aspirin i n the primary and secondary prevention of vascular disease:collaborative Meta-analysis of individual participant data from randomised trials.Lancet,2009,373(9678):1849-1860.
• [18]周金英，王莹，颜红兵.替格瑞洛单药治疗的理论依据与循证医学证据--从美国心脏病学会2020年公布的3项研究说起.中国介入心脏病学杂志，2020,28(4):228-231.
• [19]CAPRIE Steering Committee.A randomised,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).Lancet,1996,348(9038):1329-1339.
• [20]Chiarito M,Sanz-Sanchez J,Cannata F,et al.Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis:a systematic review and Metaanalysis.Lancet,2020,395(10235):1487-1495.
• [21]Watanabe H,Domei T,Morimoto T,et al.Eff ect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI:the STOPDAPT-2 randomized clinical trial.JAMA,2019,321(24):2414-2427.
• [22]Hahn JY,Song YB,Oh JH,et al.Eff ect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial.JAMA,2019,321(24):2428-2437.
• [23]Giacoppo D,Matsuda Y,Fovino LN,et al.Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs.prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents:a systematic review and Meta-analysis of randomized clinical trials.Eur Heart J,2021,42(4):308-319.
• [24]颜红兵，霍勇.《2019年欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南》--冠状动脉疾病治疗：从归类走向精准.中国介入心脏病学杂志，2019,27(7):7-9.
• [25]曾和松，颜红兵，余小平.基于基因分型导向抗血小板治疗的曙光--深度解析TAILOR PCI研究.中国介入心脏病学杂志，2020,28(4):224-227.